Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,changeToNetincome,issuanceOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,preMarketChange,preMarketChangePercent,preMarketTime,preMarketPrice,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IKT,8036571.0,25133300,,,-2637068,,-2637068,1600576,-1024695,-2625271,-2625271,,-11797,,,,0,1407165,4032436,2431860,-11797,,-2637068,-2637068,25695203.0,3837464.0,8036571.0,2783.0,1251349.0,11874035.0,10060.0,-17668692.0,2783.0,9609631.0,3588553.0,11871252.0,332774.0,248911.0,715016.0,-2082839.0,-409662.0,-409662.0,-76046.0,-4343882.0,-3934220.0,861733.0,,,8282699.0,en-US,US,EQUITY,True,Delayed Quote,2.42,1630526402,0.05000019,2.34,2.44,2.31,257641,USD,NCM,60822588,-14400000,False,False,PRE,4,-0.01999998,-0.82644546,1630571691,2.4,2.1097128,2.31 - 2.44,us_market,0,"Inhibikase Therapeutics, Inc.",2.37,0.0,0.0,11,10,finmb_113910012,NasdaqCM,"Inhibikase Therapeutics, Inc.",USD,872835,266757,0.68000007,0.39080465,1.74 - 11.8,-9.38,-0.79491526,1.74,11.8,1621267505,1621267505,1621267505,-0.62,-3.903226,2.2037144,0.2162857,0.09814598,4.4413114,-2.0213113,-0.45511588,15,America/New_York,EDT,,,,11.8,1.74,2.2037,4.4413,872.84k,266.76k,25.13M,,7.99M,21.15%,12.43%,62.34k,2.97,1.29%,0.62%,62.97k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-269.10%,-267.26%,-51.46%,-296.13%,1.83M,0.21,419.70%,-195.33k,,-4.94M,,,9.61M,0.95,1.24M,15.48,3.31,,-4.81M,-5.8M,Value,30339,Healthcare,3,"Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",Atlanta,678 392 3419,GA,1609372800,United States,http://www.inhibikase.com,86400,3350 Riverwood Parkway SE,Biotechnology,Suite 1900
t-1,IKT,9784356.0,25133300,,,-1207986,,-1207986,1144319,-56528,-1200847,-1200847,,-7139,,,,0,170416,1371263,226944,-7139,,-1207986,-1207986,24805929.0,4998350.0,9784356.0,,2325741.0,14782706.0,10051.0,-15031624.0,,13953513.0,4721889.0,14782706.0,,276461.0,1720680.0,-926639.0,-409662.0,14883873.0,53619.0,13937345.0,-946528.0,1134478.0,14786741.0,97132.0,10060817.0,en-US,US,EQUITY,True,Delayed Quote,2.42,1630526402,0.05000019,2.34,2.44,2.31,257641,USD,NCM,60822588,-14400000,False,False,PRE,4,-0.01999998,-0.82644546,1630571691,2.4,2.1097128,2.31 - 2.44,us_market,0,"Inhibikase Therapeutics, Inc.",2.37,0.0,0.0,11,10,finmb_113910012,NasdaqCM,"Inhibikase Therapeutics, Inc.",USD,872835,266757,0.68000007,0.39080465,1.74 - 11.8,-9.38,-0.79491526,1.74,11.8,1621267505,1621267505,1621267505,-0.62,-3.903226,2.2037144,0.2162857,0.09814598,4.4413114,-2.0213113,-0.45511588,15,America/New_York,EDT,,,,11.8,1.74,2.2037,4.4413,872.84k,266.76k,25.13M,,7.99M,21.15%,12.43%,62.34k,2.97,1.29%,0.62%,62.97k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-269.10%,-267.26%,-51.46%,-296.13%,1.83M,0.21,419.70%,-195.33k,,-4.94M,,,9.61M,0.95,1.24M,15.48,3.31,,-4.81M,-5.8M,Value,30339,Healthcare,3,"Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",Atlanta,678 392 3419,GA,1609372800,United States,http://www.inhibikase.com,86400,3350 Riverwood Parkway SE,Biotechnology,Suite 1900
t-2,IKT,-5125056.0,25133300,,,-670599,,-670599,580820,-82889,-663709,-663709,,-6890,,,,0,37680,701389,120569,-6890,,-670599,-670599,8690375.0,6589266.0,-5125056.0,1434336.0,1958554.0,1464210.0,8207.0,-13823638.0,1434336.0,16168.0,5914292.0,29874.0,,674974.0,3306580.0,1704241.0,-409662.0,-67132.0,-1371799.0,8383.0,75515.0,413672.0,14786741.0,-67132.0,-5884418.0,en-US,US,EQUITY,True,Delayed Quote,2.42,1630526402,0.05000019,2.34,2.44,2.31,257641,USD,NCM,60822588,-14400000,False,False,PRE,4,-0.01999998,-0.82644546,1630571691,2.4,2.1097128,2.31 - 2.44,us_market,0,"Inhibikase Therapeutics, Inc.",2.37,0.0,0.0,11,10,finmb_113910012,NasdaqCM,"Inhibikase Therapeutics, Inc.",USD,872835,266757,0.68000007,0.39080465,1.74 - 11.8,-9.38,-0.79491526,1.74,11.8,1621267505,1621267505,1621267505,-0.62,-3.903226,2.2037144,0.2162857,0.09814598,4.4413114,-2.0213113,-0.45511588,15,America/New_York,EDT,,,,11.8,1.74,2.2037,4.4413,872.84k,266.76k,25.13M,,7.99M,21.15%,12.43%,62.34k,2.97,1.29%,0.62%,62.97k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-269.10%,-267.26%,-51.46%,-296.13%,1.83M,0.21,419.70%,-195.33k,,-4.94M,,,9.61M,0.95,1.24M,15.48,3.31,,-4.81M,-5.8M,Value,30339,Healthcare,3,"Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",Atlanta,678 392 3419,GA,1609372800,United States,http://www.inhibikase.com,86400,3350 Riverwood Parkway SE,Biotechnology,Suite 1900
t-3,IKT,-4830629.0,25133300,,,-421869,,-421869,370331,-43590,-413921,-413921,,-7948,,,,0,219585,633506,263175,-7948,,-421869,-421869,8314217.0,5197268.0,-4830629.0,336290.0,1512144.0,366639.0,8193.0,-13153039.0,336290.0,7785.0,4570432.0,30349.0,,626836.0,1094040.0,77645.0,27550.0,5309.0,66781.0,-5360.0,-10669.0,266774.0,14786741.0,-22241.0,-4540083.0,en-US,US,EQUITY,True,Delayed Quote,2.42,1630526402,0.05000019,2.34,2.44,2.31,257641,USD,NCM,60822588,-14400000,False,False,PRE,4,-0.01999998,-0.82644546,1630571691,2.4,2.1097128,2.31 - 2.44,us_market,0,"Inhibikase Therapeutics, Inc.",2.37,0.0,0.0,11,10,finmb_113910012,NasdaqCM,"Inhibikase Therapeutics, Inc.",USD,872835,266757,0.68000007,0.39080465,1.74 - 11.8,-9.38,-0.79491526,1.74,11.8,1621267505,1621267505,1621267505,-0.62,-3.903226,2.2037144,0.2162857,0.09814598,4.4413114,-2.0213113,-0.45511588,15,America/New_York,EDT,,,,11.8,1.74,2.2037,4.4413,872.84k,266.76k,25.13M,,7.99M,21.15%,12.43%,62.34k,2.97,1.29%,0.62%,62.97k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",-269.10%,-267.26%,-51.46%,-296.13%,1.83M,0.21,419.70%,-195.33k,,-4.94M,,,9.61M,0.95,1.24M,15.48,3.31,,-4.81M,-5.8M,Value,30339,Healthcare,3,"Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.",Atlanta,678 392 3419,GA,1609372800,United States,http://www.inhibikase.com,86400,3350 Riverwood Parkway SE,Biotechnology,Suite 1900
